肝样胃癌的临床病理特征预后及研究展望.pptVIP

  • 5
  • 0
  • 约6.7千字
  • 约 33页
  • 2016-04-26 发布于湖北
  • 举报

肝样胃癌的临床病理特征预后及研究展望.ppt

肝样胃癌的临床病理特征预后及研究展望.ppt

我们科室AFPPGC与对照胃癌患者的总生存比较 Is chemotherapy needed in AFPGC at early stage? Recommended! Thank you! * 甲胎蛋白由新生的幼稚肝细胞分泌,胎儿的肝细胞没有发育(分化)完全,分泌的甲胎蛋白量很大,肝癌是尚未分化的肝细胞,当然能大量分泌甲胎蛋白。随着病情恶化它在血清中的含量会急剧增加 * 甲胎蛋白由新生的幼稚肝细胞分泌,胎儿的肝细胞没有发育(分化)完全,分泌的甲胎蛋白量很大,肝癌是尚未分化的肝细胞,当然能大量分泌甲胎蛋白。随着病情恶化它在血清中的含量会急剧增加 The 1-, 3-, and 5-year survival rates of AFP-positive group were 53%,35%, and 28%, respectively. The 1-, 3-, and 5-year survival rates of negative group were 95%, 57%, and 38%, respectively. The AFP-positive group had a significantly poorer survival in comparison to the stage-matched negative group (P0.01; Fig. 3). Si

文档评论(0)

1亿VIP精品文档

相关文档